This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Drummond Rennie, MD

JAMA. 1991;266(23):3333-3337.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In this issue of THE JOURNAL we publish an article by Cantekin and colleagues¹ on the utility of amoxicillin trihydrate in otitis media: an article that was submitted to JAMA in 1987 and that had already become the center of a dispute about scientific misconduct. Why has it taken so long for this article to see the light of day? Why are we publishing it?

The Cantekin Case

Developments in the Cantekin case have been reported from time to time over the last 5 years in the lay and scientific press. Readers of JAMA will find much of it rehearsed by Cantekin et al² in March 1990, and they will be able to get the flavor of this bitter dispute from the correspondence that followed.^3,4 Two congressional hearings have touched on aspects of the case.^5,6 In the briefest terms, in 1980, Dr Charles Bluestone set up . . . [Full Text PDF of this Article]

Author Affiliations
From the Office of the Deputy Editor (West), JAMA, and the Institute for Health Policy Studies, University of California at San Francisco.

Footnotes
Reprint requests to American Medical Association, 515 N State St, Chicago, IL 60610 (Dr Rennie).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?